account_balance
Investment manager · 13F filer · SEC CIK 1281446
Great Point Partners LLC
Reported value$424Mas of Jun 30, 2026
Positions37 11 new, 13 sold out
Top 10 weight53.6%VOR alone is 7%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
VORVor Biopharma Inc
7.4%Trimmed −3%
ABVXAbivax SA
6.4%New
VERAVera Therapeutics Inc
6.1%Added +201%
ZURAZura Bio Ltd
5.9%
ALMSAlumis Inc
5.7%
SLGLSol-gel Technologies Ltd
4.8%
DFTXDefinium Therapeutics Inc
4.7%New
ANNXAnnexon Inc
4.7%Added +40%
ORKAOruka Therapeutics Inc
4.1%
MLTXMoonlake Immunotherapeutics
3.9%Added +71%
SGMTSagimet Biosciences Inc
3.7%New
CTNM3.6%VORVor Biopharma Inc
7.4%Trimmed −3%
ABVX6.4%VERA6.1%ZURAZura Bio Ltd
5.9%
ALMSAlumis Inc
5.7%
SLGLSol-gel Technologies Ltd
4.8%
DFTX4.7%ANNX4.7%ORKA4.1%MLTX3.9%SGMT3.7%CTNM3.6%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
VOR Vor Biopharma Inc 7.4% Trimmed −3%ABVX Abivax SA 6.4% NewVERA Vera Therapeutics Inc 6.1% Added +201%ZURA Zura Bio Ltd 5.9% HeldALMS Alumis Inc 5.7% HeldSLGL Sol-gel Technologies Ltd 4.8% HeldDFTX Definium Therapeutics Inc 4.7% NewANNX Annexon Inc 4.7% Added +40%ORKA Oruka Therapeutics Inc 4.1% HeldMLTX Moonlake Immunotherapeutics 3.9% Added +71%SGMT Sagimet Biosciences Inc 3.7% NewCTNM Contineum Therapeutics Inc 3.6% Added +15%
What changed